Efficacy, safety and compliance of immunotherapy in the treatment of allergic rhinitis: a Meta-analysis
10.3760/cma.j.issn.1673-0860.2019.12.003
- VernacularTitle: 免疫治疗在变应性鼻炎治疗中疗效、安全性及依从性的Meta分析
- Author:
Dongxiang JI
1
;
Jiarong TAN
2
;
Hewei YU
2
Author Information
1. Pulmonary and Critical Care Medicine, Huzhou Central Hospital, Huzhou 313000, China
2. Department of Otorhinolaryngology, Huzhou Central Hospital, Huzhou 313000, China
- Publication Type:Journal Article
- Keywords:
Rhinitis, allergic;
Sublingual immunotherapy;
Subcutaneous immunotherapy;
Meta-analysis
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2019;54(12):894-901
- CountryChina
- Language:Chinese
-
Abstract:
Objective:By use of Meta analysis to compare efficacy, safety and compliance of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) on allergic rhinitis (AR).
Methods:Cochrane Library, Pubmed, Embase, CNKI Database, Wan Fang and Chinese Sci-tech Journal Database (from established time to May of 2018) were searched for trials about the AR treated by SCIT and SLIT. The relevant literatures were screened, and the randomized controlled studies were chosen. Nasal symptom scores, visual analogue scale (VAS) scores, adverse reactions and compliance were used as the outcome indicators, and the methodological quality of the literatures was evaluated strictly. The extracted data were analyzed by RevMan 5.3 and Stata 14 software.
Results:A total of 20 randomized controlled studies were included, the overall quality of which was relatively high. No publication bias was found. There was no significant difference in nasal symptom scores, VAS scores and compliance between SCIT and SLIT (SMD value was 0.03, 0.14, respectively, RR=1.12; 95%CI value was -0.17-0.23, -0.03-0.31, 0.92-1.35, respectively, all P>0.05); SLIT group resulted in lower overall incidence of adverse reactions than that of SCIT group (RR=1.79, 95%CI: 1.42-2.26, P<0.05).
Conclusion:Both SCIT and SLIT have similar eppecacy and compliance for treatment of AR, while adverse reactions are more frequently observed in SCIT.
